These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32020370)

  • 1. High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson's disease cohort.
    Fazio P; Ferreira D; Svenningsson P; Halldin C; Farde L; Westman E; Varrone A
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2407-2416. PubMed ID: 32020370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonergic dysregulation is linked to sleep problems in Parkinson's disease.
    Wilson H; Giordano B; Turkheimer FE; Chaudhuri KR; Politis M
    Neuroimage Clin; 2018; 18():630-637. PubMed ID: 29845011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [¹⁸F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [¹⁸F]FDOPA and [¹¹C]DASB PET study in Parkinson's disease.
    Pavese N; Simpson BS; Metta V; Ramlackhansingh A; Chaudhuri KR; Brooks DJ
    Neuroimage; 2012 Jan; 59(2):1080-4. PubMed ID: 21963917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease.
    Chou KL; Dayalu P; Koeppe RA; Gilman S; Spears CC; Albin RL; Kotagal V
    Mov Disord; 2022 Nov; 37(11):2301-2307. PubMed ID: 36102173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease.
    Qamhawi Z; Towey D; Shah B; Pagano G; Seibyl J; Marek K; Borghammer P; Brooks DJ; Pavese N
    Brain; 2015 Oct; 138(Pt 10):2964-73. PubMed ID: 26209314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-transcendence trait and its relationship with in vivo serotonin transporter availability in brainstem raphe nuclei: An ultra-high resolution PET-MRI study.
    Kim JH; Son YD; Kim JH; Choi EJ; Lee SY; Joo YH; Kim YB; Cho ZH
    Brain Res; 2015 Dec; 1629():63-71. PubMed ID: 26459992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter.
    Strecker K; Wegner F; Hesse S; Becker GA; Patt M; Meyer PM; Lobsien D; Schwarz J; Sabri O
    J Neurol; 2011 Jan; 258(1):19-26. PubMed ID: 20644949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.
    Wilson H; Dervenoulas G; Pagano G; Koros C; Yousaf T; Picillo M; Polychronis S; Simitsi A; Giordano B; Chappell Z; Corcoran B; Stamelou M; Gunn RN; Pellecchia MT; Rabiner EA; Barone P; Stefanis L; Politis M
    Lancet Neurol; 2019 Aug; 18(8):748-759. PubMed ID: 31229470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive loss of raphe nuclei serotonin transporter in early Parkinson's disease: A longitudinal
    Pasquini J; Ceravolo R; Brooks DJ; Bonuccelli U; Pavese N
    Parkinsonism Relat Disord; 2020 Aug; 77():170-175. PubMed ID: 30981664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic properties in functional connectivity changes and striatal dopamine deficiency in Parkinson's disease.
    Asendorf AL; Theis H; Tittgemeyer M; Timmermann L; Fink GR; Drzezga A; Eggers C; Ruppert-Junck MC; Pedrosa DJ; Hoenig MC; van Eimeren T
    Hum Brain Mapp; 2024 Jul; 45(10):e26776. PubMed ID: 38958131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved mapping and quantification of serotonin transporter availability in the human brainstem with the HRRT.
    Schain M; Tóth M; Cselényi Z; Arakawa R; Halldin C; Farde L; Varrone A
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):228-37. PubMed ID: 23076621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extrastriatal
    Nicastro N; Garibotto V; Burkhard PR
    BMC Neurol; 2020 May; 20(1):192. PubMed ID: 32416724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping the distribution of serotonin transporter in the human brainstem with high-resolution PET: Validation using postmortem autoradiography data.
    Fazio P; Schain M; Varnäs K; Halldin C; Farde L; Varrone A
    Neuroimage; 2016 Jun; 133():313-320. PubMed ID: 26994829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies.
    Pagano G; Niccolini F; Fusar-Poli P; Politis M
    Ann Neurol; 2017 Feb; 81(2):171-180. PubMed ID: 28019672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonergic mediated body mass index changes in Parkinson's disease.
    Politis M; Loane C; Wu K; Brooks DJ; Piccini P
    Neurobiol Dis; 2011 Sep; 43(3):609-15. PubMed ID: 21624463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease.
    Guttman M; Boileau I; Warsh J; Saint-Cyr JA; Ginovart N; McCluskey T; Houle S; Wilson A; Mundo E; Rusjan P; Meyer J; Kish SJ
    Eur J Neurol; 2007 May; 14(5):523-8. PubMed ID: 17437611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
    Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
    J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal DAT changes measured with [
    Kerstens VS; Fazio P; Sundgren M; Brumberg J; Halldin C; Svenningsson P; Varrone A
    Neuroimage Clin; 2023; 37():103347. PubMed ID: 36822016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An
    Joling M; Vriend C; Raijmakers PGHM; van der Zande JJ; Lemstra AW; Berendse HW; Booij J; van den Heuvel OA
    Neuroimage Clin; 2019; 22():101755. PubMed ID: 30884365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.